Search Medical Condition
Please enter condition
Please choose location

Nonthaburi, Thailand Clinical Trials

A listing of Nonthaburi, Thailand clinical trials actively recruiting patients volunteers.

RESULTS

Found (101) clinical trials

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

This study is designed to provide evidence of efficacy of S-649266 in the treatment of serious infections in adult patients with either hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP)/healthcare-associated pneumonia (HCAP), complicated urinary tract infection (cUTI), or bloodstream infections (BSI)/sepsis caused by carbapenem-resistant Gram-negative pathogens.

Phase

1.9 miles

Learn More »

Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men

The purpose of this study is to evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW). This study will enroll HIV-uninfected MSM and TGW at risk for acquiring ...

Phase

1.9 miles

Learn More »

A Study to Evaluate the Pharmacokinetics Safety Tolerability and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

This is a Phase II, open-label (all people involved know the identity of the assigned drug) and single arm study. The study will consist of a screening period of maximum 8 weeks, an initial treatment period of 48 weeks, a post week 48 treatment extension period of 4 years, and ...

Phase

1.9 miles

Learn More »

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Consenting participants will be screened and within 45 days randomly allocated to receive either dolutegravir and darunavir/ritonavir or the SOC regimen. Participants will be seen four weeks after their randomisation (week 0) visit and then at weeks 24, 48 and 96. Consenting participants will have storage samples collected and cryopreserved ...

Phase

1.9 miles

Learn More »

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Study participants receive standard therapy (induction and maintenance) for lupus nephritis in addition to receiving either placebo (no active medicine) or belimumab. Induction therapy starts before the first dose of study drug (belimumab or placebo). Maintenance therapy begins after completion of induction therapy and continues for the remainder of the ...

Phase

5.81 miles

Learn More »